EyeGate Pharma Initiates Phase I Study of EGP-437 in Patients With Non ... MarketWatch (press release) "We hope that this approach will provide more controlled local delivery of a corticosteroid through the episcleral/conjunctival plexus and will be as effective as subconjunctival injections of depot-corticosteroids, with fewer risks. |
